PE20141484A1 - Formulaciones peptidicas de liberacion controlada - Google Patents

Formulaciones peptidicas de liberacion controlada

Info

Publication number
PE20141484A1
PE20141484A1 PE2013002546A PE2013002546A PE20141484A1 PE 20141484 A1 PE20141484 A1 PE 20141484A1 PE 2013002546 A PE2013002546 A PE 2013002546A PE 2013002546 A PE2013002546 A PE 2013002546A PE 20141484 A1 PE20141484 A1 PE 20141484A1
Authority
PE
Peru
Prior art keywords
weight
preformulation
peptidic
formulations
refers
Prior art date
Application number
PE2013002546A
Other languages
English (en)
Inventor
Fredrik Tiberg
Catalin Nistor
Markus Johnsson
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46456496&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141484(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of PE20141484A1 publication Critical patent/PE20141484A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

SE REFIERE A UNA PREFORMULACION QUE COMPRENDE UNA MEZCLA DE BAJA VISCOSIDAD QUE COMPRENDE: a) 20-80% EN PESO DE UN DIACILGLICEROL Y/O UN TOCOFEROL; b) 20-80% EN PESO DE UNA FOSFATIDILCOLINA (PC); c) 5-20% EN PESO DE UN SOLVENTE MONO-ALCOHOLICO ORGANICO, BIOCOMPATIBLE; d) HASTA 20% EN PESO DE SOLVENTE POLAR TAL COMO AGUA, PROPILENGLICOL O MEZCLA DE LOS MISMOS; e) UN AGENTE ACTIVO PEPTIDICO TAL COMO UN ANALOGO DE SOMATOSTATINA; Y f) UN ANTIOXIDANTE TAL COMO ACIDO ASCORBICO, EDTA O ACIDO CITRICO; DONDE LA RELACION DE COMPONENTES a:b ESTA DENTRO DEL RANGO 40:60 A 54:46; DONDE LA PREFORMULACION FORMA UNA ESTRUCTURA DE FASE CRISTALINA LIQUIDA LUEGO DEL CONTACTO CON FLUIDO ACUOSO EN EXCESO. SE REFIERE TAMBIEN A UN PROCESO PARA LA FORMACION DE DICHA PREFORMULACION, A DISPOSITIVOS Y KITS DE ADMINISTRACION
PE2013002546A 2011-05-25 2012-05-25 Formulaciones peptidicas de liberacion controlada PE20141484A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161489886P 2011-05-25 2011-05-25

Publications (1)

Publication Number Publication Date
PE20141484A1 true PE20141484A1 (es) 2014-10-31

Family

ID=46456496

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002546A PE20141484A1 (es) 2011-05-25 2012-05-25 Formulaciones peptidicas de liberacion controlada

Country Status (28)

Country Link
US (2) US11433120B2 (es)
EP (1) EP2714004B1 (es)
JP (2) JP6265888B2 (es)
KR (1) KR102066755B1 (es)
CN (2) CN108283619B (es)
AR (1) AR086577A1 (es)
AU (2) AU2012260821B2 (es)
BR (1) BR112013030104A8 (es)
CA (1) CA2836847C (es)
CL (1) CL2013003365A1 (es)
CO (1) CO6900117A2 (es)
CR (1) CR20130653A (es)
CU (1) CU20130158A7 (es)
DK (1) DK2714004T3 (es)
DO (1) DOP2013000275A (es)
EA (1) EA036213B1 (es)
EC (1) ECSP13013107A (es)
GT (1) GT201300292A (es)
IL (1) IL229376B (es)
MX (1) MX361716B (es)
MY (1) MY177820A (es)
NI (1) NI201300127A (es)
PE (1) PE20141484A1 (es)
PH (1) PH12013502550B1 (es)
SG (1) SG194865A1 (es)
TW (1) TWI624271B (es)
WO (1) WO2012160213A1 (es)
ZA (1) ZA201309653B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1768650B1 (en) * 2004-06-04 2008-07-16 Camurus Ab Liquid depot formulations
US9107904B2 (en) 2012-04-05 2015-08-18 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
MX350964B (es) * 2012-05-25 2017-09-27 Camurus Ab Formulaciones de agonistas del receptor de somatostatina.
EP2877155B1 (en) 2012-07-26 2020-10-28 Camurus AB Opioid formulations
US10300145B2 (en) 2016-07-15 2019-05-28 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
CA3036307A1 (en) 2016-09-15 2018-03-22 Camurus Ab Prostacyclin analogue formulations
CN109789215B (zh) * 2016-09-27 2022-12-16 卡姆拉斯公司 含有生长激素抑制素受体激动剂的制剂
BR112019011053A2 (pt) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc moduladores da atividade do complemento
CN112188898A (zh) * 2017-11-15 2021-01-05 节奏制药公司 缓释肽配制品
CN109091451B (zh) * 2018-09-10 2021-08-13 武汉百纳礼康生物制药有限公司 亲水性药物的油相液晶凝胶前体制剂及其制备方法
CN113993535A (zh) * 2019-05-29 2022-01-28 卡姆拉斯公司 脂质控释组合物
CN113368041B (zh) * 2020-07-17 2023-01-03 丽珠医药集团股份有限公司 药物组合物、缓释制剂及其制备方法
JP2024517204A (ja) * 2021-05-04 2024-04-19 カムルス エービー 神経内分泌腫瘍を治療するための組成物及び方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046642A1 (en) * 2003-11-07 2005-05-26 Camurus Ab Compositions of lipids and cationic peptides
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
EP1768650B1 (en) * 2004-06-04 2008-07-16 Camurus Ab Liquid depot formulations
GB0417388D0 (en) 2004-08-04 2004-09-08 Camurus Ab Composition
KR101234885B1 (ko) 2004-08-04 2013-02-19 카무러스 에이비 비층상 분산을 형성하는 조성물
ES2343641T3 (es) * 2005-01-14 2010-08-05 Camurus Ab Formulaciones bioadhesivas topicas.
PL1843746T3 (pl) * 2005-01-14 2011-09-30 Camurus Ab Formulacje analogów somatostatyny
EP1843751B1 (en) * 2005-01-21 2020-09-30 Camurus Ab Pharmaceutical lipid compositions
ATE509634T1 (de) * 2005-04-08 2011-06-15 Amylin Pharmaceuticals Inc Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
DK1888031T3 (da) * 2005-06-06 2013-02-18 Camurus Ab GLP-1-analogformuleringer
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
US8931272B2 (en) * 2010-10-29 2015-01-13 Ford Global Technologies, Llc Method and system for limiting output of a boosted engine
BR112014013693B1 (pt) * 2011-12-05 2023-01-31 Camurus Ab Pré-formulação, e, uso de uma pré-formulação
MX350964B (es) * 2012-05-25 2017-09-27 Camurus Ab Formulaciones de agonistas del receptor de somatostatina.
US20230285502A1 (en) * 2016-09-07 2023-09-14 Camurus Ab Mixtures and formulations
CN109789215B (zh) * 2016-09-27 2022-12-16 卡姆拉斯公司 含有生长激素抑制素受体激动剂的制剂

Also Published As

Publication number Publication date
MX2013013401A (es) 2013-12-12
US20140162944A1 (en) 2014-06-12
ECSP13013107A (es) 2015-03-31
US11433120B2 (en) 2022-09-06
AR086577A1 (es) 2014-01-08
GT201300292A (es) 2014-08-05
CU20130158A7 (es) 2014-04-24
CR20130653A (es) 2014-03-05
BR112013030104A2 (pt) 2016-09-20
CA2836847A1 (en) 2012-11-29
JP6415673B2 (ja) 2018-10-31
CN108283619A (zh) 2018-07-17
NZ617828A (en) 2016-11-25
IL229376B (en) 2019-11-28
CN103702662B (zh) 2018-07-20
MX361716B (es) 2018-12-14
EP2714004A1 (en) 2014-04-09
NI201300127A (es) 2014-02-25
CO6900117A2 (es) 2014-03-20
JP2018076327A (ja) 2018-05-17
AU2012260821B2 (en) 2016-01-07
ZA201309653B (en) 2016-05-25
KR102066755B1 (ko) 2020-01-15
PH12013502550A1 (en) 2015-08-10
WO2012160213A1 (en) 2012-11-29
AU2016202156A1 (en) 2016-04-28
CA2836847C (en) 2021-06-29
EA201391675A1 (ru) 2014-08-29
US20210308226A1 (en) 2021-10-07
BR112013030104A8 (pt) 2021-09-08
CL2013003365A1 (es) 2014-07-25
MY177820A (en) 2020-09-23
JP2014520090A (ja) 2014-08-21
EA036213B1 (ru) 2020-10-14
PH12013502550B1 (en) 2015-08-10
CN103702662A (zh) 2014-04-02
DK2714004T3 (da) 2024-06-10
CN108283619B (zh) 2021-09-14
AU2016202156B2 (en) 2018-03-22
EP2714004B1 (en) 2024-05-15
KR20140045438A (ko) 2014-04-16
JP6265888B2 (ja) 2018-01-24
TW201249463A (en) 2012-12-16
TWI624271B (zh) 2018-05-21
SG194865A1 (en) 2013-12-30
DOP2013000275A (es) 2014-05-15
IL229376A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
PE20141484A1 (es) Formulaciones peptidicas de liberacion controlada
CL2018003452A1 (es) Formulaciones nasales semi-sólidas y líquidas visuales de cannabinoides.
CU24400B1 (es) Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas
AR106049A1 (es) Formulaciones de liberación controlada
PE20191714A1 (es) Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso
PE20141297A1 (es) Formulaciones peptidicas robustas de liberacion controlada
CO7240372A2 (es) Formulaciones farmacéuticas tópicas no acuosas
AR083016A1 (es) Formulaciones liquidas para la agricultura con una mejor estabilidad
GT201600060A (es) Formulaciones de espuma y aparatos para suminstro
CO2019012814A2 (es) Composición farmacéutica líquida estable
EA201791166A1 (ru) Препараты с контролируемым высвобождением
BR112014010812A2 (pt) anticongelante de gema de ovo de pato para criopreservação de sêmen de jumento e respectivo método de preparação
AR099097A1 (es) SUSPOEMULSIÓN ACUOSA QUE CONTIENE l-CIALOTRINA Y MÉTODOS PARA PRODUCIR Y USAR LA MISMA
BR112017017643A2 (pt) formulação farmacêutica tópica
CO2021016449A2 (es) Composiciones terapéuticas estables en solventes polares aproticos y métodos de fabricación de las mismas
PH12014502614A1 (en) Somatostatin receptor agonist formulations
AR098351A1 (es) Sistema ruptor doble para reducir los daños en las formaciones durante la fracturación
CL2020000551A1 (es) Formulación de uso tópico para el control y la prevención de parásitos en animales.
CL2018003793A1 (es) Reducción de deriva de pulverización.
PE20220416A1 (es) Formulacion agricola
PE20131029A1 (es) Composicion pesticida
CO2018000526A2 (es) Concentrado que contiene alprostadil
PE20171305A1 (es) Formulaciones inyectables de paracetamol
CO2018000525A2 (es) Concentrado que contiene alprostadil
ECSP12012340A (es) Composicion pesticida

Legal Events

Date Code Title Description
FG Grant, registration